Seattle Genetics Q3 top line up 26%; revenue guidance raised

Seattle Genetics (NASDAQ:SGEN) Q3 results:

Revenues: $213.3M (+25.9%); product sales: $167.6M (+32.0%).

Net loss: ($91.9M) (-36.4%); loss/share: ($0.55) (-31.0%).

2019 guidance: Revenues: $825M – 860M from $805M – 855M; Adcetris sales: $625M – 640M from $610M – 640M.

Previously: Seattle Genetics EPS misses by $0.19, beats on revenue (Oct. 29)

https://seekingalpha.com/news/3511177-seattle-genetics-q3-top-line-26-percent-revenue-guidance-raised